Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Immunitybio Inc
IBRXCurrent price
2.47 USD
0 USD (0.00%)
Last closed
2.72 USD
Company
immunitybio.com
ISIN
US45256X1037
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 179 693 568 USD
Yield for 12 month
-50.00 %
1Y
3Y
5Y
10Y
15Y
IBRX
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California. Address: 3530 John Hopkins Court, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
11.25 USDP/E ratio
–Dividend Yield
–Current Year
+14 745 000 USD
Last Year
+622 000 USD
Current Quarter
+7 552 000 USD
Last Quarter
+6 106 000 USD
Current Year
+14 745 000 USD
Last Year
+622 000 USD
Current Quarter
+7 552 000 USD
Last Quarter
+6 106 000 USD
Key Figures IBRX
1 year
3 years
5 years
10 years
EBITDA
-326 628 992 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-48.48 %
PEG Ratio
–
Return On Equity TTM
–
Wall Street Target Price
11.25 USD
Revenue TTM
14 745 000 USD
Book Value
-0.57 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
5 333.10 %
Dividend Yield
–
Gross Profit TTM
14 745 000 USD
Earnings per share
-0.62 USD
Diluted Eps TTM
-0.62 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics IBRX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History IBRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation IBRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
171.86
Price Sales TTM
147.83
Enterprise Value EBITDA
-8.99
Price Book MRQ
–
Financials IBRX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators IBRX
For 52 weeks
2.28 USD
10.53 USD
50 Day MA
2.99 USD
Shares Short Prior Month
59 544 447
200 Day MA
3.87 USD
Short Ratio
10.24
Shares Short
63 183 105
Short Percent
19.85 %
BeatStart